Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) - Net Assets

Latest as of March 2026: CN¥2.28 Billion CNY ≈ $334.00 Million USD

Based on the latest financial reports, Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has net assets worth CN¥2.28 Billion CNY (≈ $334.00 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.40 Billion ≈ $351.21 Million USD) and total liabilities (CN¥117.63 Million ≈ $17.21 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Hubei Biocause Heilen Pharmaceutical Co. (301211) tangible net worth to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥2.28 Billion
% of Total Assets	95.1%
Annual Growth Rate	28.4%
5-Year Change	2.27%
10-Year Change	N/A
Growth Volatility	69.03

Hubei Biocause Heilen Pharmaceutical Co. Ltd. - Net Assets Trend (2017–2025)

This chart illustrates how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. See 301211 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2017–2025)

The table below shows the annual net assets of Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2017 to 2025. For live valuation and market cap data, see market cap of Hubei Biocause Heilen Pharmaceutical Co..

Year	Net Assets	Change
2025-12-31	CN¥2.27 Billion ≈ $332.64 Million	-1.58%
2024-12-31	CN¥2.31 Billion ≈ $337.98 Million	-1.99%
2023-12-31	CN¥2.36 Billion ≈ $344.86 Million	+3.52%
2022-12-31	CN¥2.28 Billion ≈ $333.12 Million	+2.42%
2021-12-31	CN¥2.22 Billion ≈ $325.26 Million	+217.36%
2020-12-31	CN¥700.39 Million ≈ $102.49 Million	+43.45%
2019-12-31	CN¥488.25 Million ≈ $71.45 Million	+22.10%
2018-12-31	CN¥399.87 Million ≈ $58.51 Million	+29.98%
2017-12-31	CN¥307.65 Million ≈ $45.02 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 23404981728.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥167.37 Million	7.36%
Other Components	CN¥2.11 Billion	92.64%
Total Equity	CN¥2.27 Billion	100.00%

Hubei Biocause Heilen Pharmaceutical Co. Ltd. Competitors by Market Cap

The table below lists competitors of Hubei Biocause Heilen Pharmaceutical Co. Ltd. ranked by their market capitalization.

Company	Market Cap
Neogen Chemicals Limited NSE:NEOGEN	$571.37 Million
Australian Agricultural Company Ltd AU:AAC	$571.50 Million
Vibhavadi Medical Center Public Company Limited BK:VIBHA	$571.62 Million
Sincere Navigation Corp TW:2605	$571.70 Million
Everspin Technologies Inc NASDAQ:MRAM	$571.18 Million
Jamna Auto Industries Limited NSE:JAMNAAUTO	$571.18 Million
GENERAL Elevator Co. Ltd. SHE:300931	$571.04 Million
Guolin Environmental Tech Co Ltd SHE:300786	$570.86 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 2,309,688,533 to 2,273,228,082, a change of -36,460,451 (-1.6%).
Net income of 34,910,599 contributed positively to equity growth.
Dividend payments of 72,000,000 reduced retained earnings.
Other comprehensive income decreased equity by 57,621,539.
Other factors increased equity by 58,250,490.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥34.91 Million	+1.54%
Dividends Paid	CN¥72.00 Million	-3.17%
Other Comprehensive Income	CN¥-57.62 Million	-2.53%
Other Changes	CN¥58.25 Million	+2.56%
Total Change	CN¥-	-1.58%

Book Value vs Market Value Analysis

This analysis compares Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.72x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 11.71x to 1.72x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	CN¥0.80	CN¥9.35	x
2018-12-31	CN¥0.93	CN¥9.35	x
2019-12-31	CN¥1.57	CN¥9.35	x
2020-12-31	CN¥2.23	CN¥9.35	x
2021-12-31	CN¥7.14	CN¥9.35	x
2022-12-31	CN¥5.49	CN¥9.35	x
2023-12-31	CN¥5.63	CN¥9.35	x
2024-12-31	CN¥5.57	CN¥9.35	x
2025-12-31	CN¥5.44	CN¥9.35	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Hubei Biocause Heilen Pharmaceutical Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 1.54%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 7.70%
• Asset Turnover: 0.19x
• Equity Multiplier: 1.06x
Recent ROE (1.54%) is below the historical average (9.95%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2017	4.32%	2.80%	0.69x	2.25x	CN¥-13.49 Million
2018	16.69%	9.23%	0.81x	2.24x	CN¥19.13 Million
2019	20.54%	15.19%	0.89x	1.53x	CN¥51.46 Million
2020	24.00%	28.35%	0.74x	1.15x	CN¥98.03 Million
2021	5.47%	22.50%	0.23x	1.05x	CN¥-100.63 Million
2022	5.53%	24.43%	0.21x	1.10x	CN¥-101.86 Million
2023	7.47%	26.56%	0.26x	1.08x	CN¥-59.55 Million
2024	3.96%	20.53%	0.18x	1.08x	CN¥-139.42 Million
2025	1.54%	7.70%	0.19x	1.06x	CN¥-192.41 Million

Industry Comparison

This section compares Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $3,632,988,841
Average return on equity (ROE) among peers: 4.16%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211)	CN¥2.28 Billion	4.32%	0.05x	$571.36 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$1.97 Billion	4.04%	0.54x	$565.97 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$654.09 Million	2.17%	0.78x	$359.03 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$0.00	0.00%	0.00x	$4.30 Billion
Livzon Pharmaceutical Group Inc (000513)	$973.90 Million	0.17%	0.60x	$2.52 Billion
Wedge Industrial Co Ltd (000534)	$1.29 Billion	11.69%	1.47x	$2.41 Billion
Yunnan Baiyao Group Co Ltd (000538)	$3.19 Billion	14.61%	0.55x	$12.64 Billion
Hainan Haiyao Co Ltd (000566)	$353.98 Million	-9.58%	0.80x	$715.72 Million
Tus Pharmaceutical Group Co Ltd (000590)	$307.22 Million	6.68%	0.79x	$319.94 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$2.55 Billion	4.67%	3.16x	$916.75 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$25.04 Billion	7.11%	0.16x	$3.00 Billion

About Hubei Biocause Heilen Pharmaceutical Co. Ltd.

SHE:301211 China Drug Manufacturers - Specialty & Generic

Market Cap

$571.36 Million

CN¥3.90 Billion CNY

Market Cap Rank

#11703 Global

#3369 in China

Share Price

CN¥9.35

Change (1 day)

+0.75%

52-Week Range

CN¥9.28 - CN¥20.13

All Time High

CN¥44.40